Semiquantified noncalcified coronary plaque in systemic lupus erythematosus

Adnan Kiani, Jens Vogel-Claussen, Armin Zadeh, Laurence S. Magder, Joao Lima, Michelle Petri

Research output: Contribution to journalArticle

Abstract

Objective. A major cause of morbidity and mortality in systemic lupus erythematosus (SLE) is accelerated coronary atherosclerosis. New technology (computed tomographic angiography) can measure noncalcified coronary plaque (NCP), which is more prone to rupture. We report on a study of semiquantified NCP in SLE. Methods. Patients with SLE (n = 147) with no history of cardiovascular disease underwent 64-slice coronary multidetector computed tomography (MDCT). The MDCT scans were evaluated quantitatively by a radiologist, using dedicated software. Results. The group of 147 patients with SLE was 86% female, 70% white, 29% African American, and 3% other ethnicity. The mean age was 51 years. In our univariate analysis, the major traditional cardiovascular risk factors associated with noncalcified plaque were age (p = 0.007), obesity (p = 0.03; measured as body mass index), homocysteine (p = 0.05), and hypertension (p = 0.04). Anticardiolipin (p = 0.026; but not lupus anticoagulant) and anti-dsDNA (p = 0.03) were associated with higher noncalcified plaque. Prednisone and hydroxychloroquine therapy had no effect, but methotrexate (MTX) use was associated with higher noncalcified plaque (p = 0.0001). In the best multivariate model, age, current MTX use, and history of anti-dsDNA remained significant. Conclusion. Our results suggest that serologic SLE (anti-dsDNA) and traditional cardiovascular risk factors contribute to semiquantified noncalcified plaque in SLE. The association with MTX is not understood, but should be replicated in larger studies and in multiple centers. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)2286-2293
Number of pages8
JournalJournal of Rheumatology
Volume39
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Systemic Lupus Erythematosus
Methotrexate
Multidetector Computed Tomography
Hydroxychloroquine
Lupus Coagulation Inhibitor
Rheumatology
Homocysteine
Prednisone
African Americans
Coronary Artery Disease
Rupture
Angiography
Body Mass Index
Cardiovascular Diseases
Software
Obesity
Hypertension
Technology
Morbidity
Mortality

Keywords

  • Cardiovascular disease
  • Comorbidity
  • Risk factors
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Semiquantified noncalcified coronary plaque in systemic lupus erythematosus. / Kiani, Adnan; Vogel-Claussen, Jens; Zadeh, Armin; Magder, Laurence S.; Lima, Joao; Petri, Michelle.

In: Journal of Rheumatology, Vol. 39, No. 12, 12.2012, p. 2286-2293.

Research output: Contribution to journalArticle

Kiani, Adnan ; Vogel-Claussen, Jens ; Zadeh, Armin ; Magder, Laurence S. ; Lima, Joao ; Petri, Michelle. / Semiquantified noncalcified coronary plaque in systemic lupus erythematosus. In: Journal of Rheumatology. 2012 ; Vol. 39, No. 12. pp. 2286-2293.
@article{c321e7e3b87f46999a335967670342b9,
title = "Semiquantified noncalcified coronary plaque in systemic lupus erythematosus",
abstract = "Objective. A major cause of morbidity and mortality in systemic lupus erythematosus (SLE) is accelerated coronary atherosclerosis. New technology (computed tomographic angiography) can measure noncalcified coronary plaque (NCP), which is more prone to rupture. We report on a study of semiquantified NCP in SLE. Methods. Patients with SLE (n = 147) with no history of cardiovascular disease underwent 64-slice coronary multidetector computed tomography (MDCT). The MDCT scans were evaluated quantitatively by a radiologist, using dedicated software. Results. The group of 147 patients with SLE was 86{\%} female, 70{\%} white, 29{\%} African American, and 3{\%} other ethnicity. The mean age was 51 years. In our univariate analysis, the major traditional cardiovascular risk factors associated with noncalcified plaque were age (p = 0.007), obesity (p = 0.03; measured as body mass index), homocysteine (p = 0.05), and hypertension (p = 0.04). Anticardiolipin (p = 0.026; but not lupus anticoagulant) and anti-dsDNA (p = 0.03) were associated with higher noncalcified plaque. Prednisone and hydroxychloroquine therapy had no effect, but methotrexate (MTX) use was associated with higher noncalcified plaque (p = 0.0001). In the best multivariate model, age, current MTX use, and history of anti-dsDNA remained significant. Conclusion. Our results suggest that serologic SLE (anti-dsDNA) and traditional cardiovascular risk factors contribute to semiquantified noncalcified plaque in SLE. The association with MTX is not understood, but should be replicated in larger studies and in multiple centers. The Journal of Rheumatology",
keywords = "Cardiovascular disease, Comorbidity, Risk factors, Systemic lupus erythematosus",
author = "Adnan Kiani and Jens Vogel-Claussen and Armin Zadeh and Magder, {Laurence S.} and Joao Lima and Michelle Petri",
year = "2012",
month = "12",
doi = "10.3899/jrheum.120197",
language = "English (US)",
volume = "39",
pages = "2286--2293",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "12",

}

TY - JOUR

T1 - Semiquantified noncalcified coronary plaque in systemic lupus erythematosus

AU - Kiani, Adnan

AU - Vogel-Claussen, Jens

AU - Zadeh, Armin

AU - Magder, Laurence S.

AU - Lima, Joao

AU - Petri, Michelle

PY - 2012/12

Y1 - 2012/12

N2 - Objective. A major cause of morbidity and mortality in systemic lupus erythematosus (SLE) is accelerated coronary atherosclerosis. New technology (computed tomographic angiography) can measure noncalcified coronary plaque (NCP), which is more prone to rupture. We report on a study of semiquantified NCP in SLE. Methods. Patients with SLE (n = 147) with no history of cardiovascular disease underwent 64-slice coronary multidetector computed tomography (MDCT). The MDCT scans were evaluated quantitatively by a radiologist, using dedicated software. Results. The group of 147 patients with SLE was 86% female, 70% white, 29% African American, and 3% other ethnicity. The mean age was 51 years. In our univariate analysis, the major traditional cardiovascular risk factors associated with noncalcified plaque were age (p = 0.007), obesity (p = 0.03; measured as body mass index), homocysteine (p = 0.05), and hypertension (p = 0.04). Anticardiolipin (p = 0.026; but not lupus anticoagulant) and anti-dsDNA (p = 0.03) were associated with higher noncalcified plaque. Prednisone and hydroxychloroquine therapy had no effect, but methotrexate (MTX) use was associated with higher noncalcified plaque (p = 0.0001). In the best multivariate model, age, current MTX use, and history of anti-dsDNA remained significant. Conclusion. Our results suggest that serologic SLE (anti-dsDNA) and traditional cardiovascular risk factors contribute to semiquantified noncalcified plaque in SLE. The association with MTX is not understood, but should be replicated in larger studies and in multiple centers. The Journal of Rheumatology

AB - Objective. A major cause of morbidity and mortality in systemic lupus erythematosus (SLE) is accelerated coronary atherosclerosis. New technology (computed tomographic angiography) can measure noncalcified coronary plaque (NCP), which is more prone to rupture. We report on a study of semiquantified NCP in SLE. Methods. Patients with SLE (n = 147) with no history of cardiovascular disease underwent 64-slice coronary multidetector computed tomography (MDCT). The MDCT scans were evaluated quantitatively by a radiologist, using dedicated software. Results. The group of 147 patients with SLE was 86% female, 70% white, 29% African American, and 3% other ethnicity. The mean age was 51 years. In our univariate analysis, the major traditional cardiovascular risk factors associated with noncalcified plaque were age (p = 0.007), obesity (p = 0.03; measured as body mass index), homocysteine (p = 0.05), and hypertension (p = 0.04). Anticardiolipin (p = 0.026; but not lupus anticoagulant) and anti-dsDNA (p = 0.03) were associated with higher noncalcified plaque. Prednisone and hydroxychloroquine therapy had no effect, but methotrexate (MTX) use was associated with higher noncalcified plaque (p = 0.0001). In the best multivariate model, age, current MTX use, and history of anti-dsDNA remained significant. Conclusion. Our results suggest that serologic SLE (anti-dsDNA) and traditional cardiovascular risk factors contribute to semiquantified noncalcified plaque in SLE. The association with MTX is not understood, but should be replicated in larger studies and in multiple centers. The Journal of Rheumatology

KW - Cardiovascular disease

KW - Comorbidity

KW - Risk factors

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84870342885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870342885&partnerID=8YFLogxK

U2 - 10.3899/jrheum.120197

DO - 10.3899/jrheum.120197

M3 - Article

C2 - 23027889

AN - SCOPUS:84870342885

VL - 39

SP - 2286

EP - 2293

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 12

ER -